Survival based on stage, LDH, and MYC rearrangement. Kaplan-Meier curves of (A) PFS- and (B) OS-based on Ann Arbor stage. The 3-year PFS of patients with stage 1, 2, 3, or 4 BL were 78% (95% CI, 65-87), 83% (95% CI, 72-90), 62% (95% CI, 44-76), and 60% (95% CI, 55-64), respectively (P < .001); corresponding 3-year OS rates were 81% (95% CI, 67-89), 87% (95% CI, 77-93), 74% (95% CI, 56-96), and 65% (95% CI, 60-69), respectively (P < .001). Kaplan-Meier curves of (C) PFS- and (D) OS-based increasing LDH (normalized to the upper limit of normal in the institution). The 3-year PFS for patients with LDH levels that were normal, 1 to 3× normal, 3 to 5× normal, 5 to 10× normal, and >10× normal were 77% (95% CI, 69-84), 74% (95% CI, 67-79), 58% (95% CI, 46-68), 53% (95% CI, 41-63), and 46% (95% CI, 35-56), respectively (P < .001); 3-year OS rates were 81% (95% CI, 73-83), 78% (95% CI, 72-84), 67% (95% CI, 55-77), 58% (95% CI, 46-68), and 49% (95% CI, 38-60), respectively (P < .001). Kaplan-Meier curves of PFS (E) and (F) OS for patients according to reported MYC rearrangement status. The 3-year PFS rates for patients with MYC-IGH rearrangement, MYC-IGK/IGL rearrangement, MYC rearrangement by break-apart (BA) probe only, and negative or unknown rearrangement were 64% (95% CI, 59-68) 54% (95% CI, 33-71), 67% (95% CI, 58-74), and 68% (95% CI, 55-78), respectively (P = .52); corresponding 3-year OS rates were 69% (95% CI, 64-74), 62% (95% CI, 41-77), 71% (95% CI, 63-78), and 70% (95% CI, 57-80), respectively (P = .46).